Q1 2024 13F Holders as of 31 Mar 2024
-
Type / Class
-
Equity / Common Shares
-
Shares outstanding
-
124,058,172
-
Total 13F shares
-
34,683,534
-
Share change
-
-1,223,140
-
Total reported value
-
$155,728,721
-
Put/Call ratio
-
36%
-
Price per share
-
$4.49
-
Number of holders
-
37
-
Value change
-
-$1,535,321
-
Number of buys
-
16
-
Number of sells
-
21
Institutional Holders of ADC Therapeutics SA - Common Shares (ADCT) as of Q1 2024
As of 31 Mar 2024,
ADC Therapeutics SA - Common Shares (ADCT) was held by
37 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
34,683,534 shares.
The largest 10 holders included
Redmile Group, LLC, Prosight Management, LP, MORGAN STANLEY, GOLDMAN SACHS GROUP INC, BANK OF AMERICA CORP /DE/, MILLENNIUM MANAGEMENT LLC, ADAGE CAPITAL PARTNERS GP, L.L.C., CITADEL ADVISORS LLC, Vantage Consulting Group Inc, and Blue Owl Capital Holdings LP.
This page lists
36
institutional shareholders reporting positions in this security
for the Q1 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.